News

News 18.11.2021 Zurich-Schlieren, Switzerland, November 18, 2021. Proteomedix, the Swiss diagnostics company committed to advance prostate cancer care, today announced the publication of clinical data that reveal added prognostic value of a blood biomarker signature predicting biochemical recurrence and adverse pathology in prostate cancer patients. Radical prostatectomy provides excellent cancer control of clinically...

News 16.11.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that a planned futility analysis of ensovibep...

News 09.11.2021 Schlieren, SWITZERLAND – November 5, 2021 – GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics AG, from which GlycoEra was spun-out, also...

Events, Internal events
Event date: 01.12.2021 5pm - 7pm GMT at Auditorium, Wagistrasse 25 Creoptix and 2Bind invite for an after-work networking event about the latest dynamics and trends in the molecular binding analysis field. Expert in kinetics, Dr. Thomas Schubert from 2Bind, will discuss the importance of reliable molecular binding characterization in antibody and small molecule development....

News 04.11.2021 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced dose administration for the first patient in a Phase 1 first-in-human study evaluating the...